Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review

Current Diabetes Reports

Volumn 14, Issue 7, 2014, Pages

  Jørgensen, Marit Eika ^a   Faurholt Jepsen, Daniel ^b,c  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Diabetes; Glucose lowering treatment; Glycemic control; Tuberculosis incidence; Tuberculosis outcome

Indexed keywords

ANTIDIABETIC AGENT; ETHAMBUTOL; GLUCOSE; INSULIN; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; SAXAGLIPTIN; GLUCOSE BLOOD LEVEL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; MEDICAL SUBJECT HEADINGS; MEDLINE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PREVALENCE; PROGNOSIS; SCREENING TEST; SPUTUM CULTURE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PROGNOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84901729028     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0505-1     Document Type: Article

References (61)

1. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.
2. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737-46. The study reviews the knowledge about the co-existence of diabetes and tuberculosis and potential mechanisms underlying the bidirectional association.
3. Dooley KE, Tang T, Golub JE, et al. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80:634-9.
4. WHO, International Union Against TB Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. 2011. Available at: http://www.who.int/diabetes/publications/tb-diabetes2011/en/index.html (accessed 28 Dec 2011). This WHO paper provides a statement on bidirectional management of diabetes in tuberculosis patients and vice versa.
5. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343. doi: 10.1136/bmj.d6898. The meta-analysis document both health benefits and adverse risks associated with intensive glycemic control of diabetes.
6. Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis. 2013;13:436-48. The paper focuses on synergies, and challenges of integration of tuberculosis care with management strategies for noncommunicable and communicable diseases.
7. Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2005;9:777-83.
8. Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2008;137:203-10.
9. Restrepo BI, Fisher-Hoch SP, Crespo JG, et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect. 2007;135:483-91.
10. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45:428-35.
11. Faurholt-Jepsen D, Range N, PrayGod G, et al. The role of diabetes on the clinical manifestations of pulmonary tuberculosis. Trop Med Int Health. 2012;17:877-83.
12. Tatar D, Senol G, Alptekin S, et al. Tuberculosis in diabetics: features in an endemic area. Jpn J Infect Dis. 2009;62:423-7.
13. Chang J-T, Dou H-Y, Yen C-L, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011;110:372-81.
14. Faurholt-Jepsen D, Range N, Praygod G, et al. The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from mwanza, Tanzania. BMC Infect Dis. 2012;12:165.
15. Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health. 2013;18:822-9.
16. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013;68:214-20.
17. Magee MJ, Bloss E, Shin SS, et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis. 2013;17:e404-12.
18. Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012. doi: 10.1155/2012/645362.
19. Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002;6:1114-7.
20. Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013;56:770-6.
21. Kang YA, Kim SY, Jo K-W, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respir Int Rev Thorac Dis. [Published Online First: May 8, 2013]. doi: 10.1159/000348374.
22. Kuo S-C, Chen Y-T, Li S-Y, et al. Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study. BMC Infect Dis. 2013;13:351.
23. Mi F, Tan S, Liang L, et al. Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China. Trop Med Int Health. 2013;18:1379-85.
24. Nandakumar N, Duraisamy K, Balakrishnan S, et al. Outcome of tuberculosis treatment in patients with diabetes mellitus treated in the Revised National Tuberculosis Control Programme in Malappuram District, Kerala, India. PLoS One. 2013;8:e76275. doi: 10.1371/journal.pone.0076275.
25. Orofino Rde L, do Brasil PEA, Trajman A, et al. Predictors of tuberculosis treatment outcomes. J Bras Pneumol Publicacao. 2012;38:88-97.
26. Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One. 2013;8:e58044. doi: 10.1371/journal.pone. 0058044.
27. Reis-Santos B, Locatelli R, Horta BL, et al. Socio-demographic and clinical differences in subjects with tuberculosis with and without diabetes mellitus in Brazil - a multivariate analysis. PLoS One. 2013;8:e62604. doi: 10.1371/journal.pone.0062604.
28. Singla R, Khan N, Al-Sharif N, et al. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis. 2006;10:74-9.
29. Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8:e82943. doi: 10.1371/journal.pone.0082943.
30. Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137:203-10.
31. Wang J-Y, Lee L-N, Yu C-J, et al. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology. 2009;14:1012-9.
32. Chiang C-Y, Lee J-J, Yu M-C, et al. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int J Tuberc Lung Dis. 2009;13:105-11.
33. Lisha PV, James PT, Ravindran C. Morbidity and mortality at five years after initiating Category I treatment among patients with new sputum smear positive pulmonary tuberculosis. Indian J Tuberc. 2012;59:83-91.
34. Picon PD, Bassanesi SL, Caramori MLA, et al. Risk factors for recurrence of tuberculosis. J Bras Pneumol Publicaçao. 2007;33:572-8.
35. Banu Rekha VV, Balasubramanian R, Swaminathan S, et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian J Med Res. 2007;126:452-8.
36. Tam CM, Leung CC, Noertjojo K, et al. Tuberculosis in Hong Kong-patient characteristics and treatment outcome. Hong Kong Med J. 2003;9:83-90.
37. Uzundaǧ Işeri A, Dulkar G, Selçuk Sönmez O, et al. Factors that affect sputum culture conversion rate in hospitalized patients with pulmonary tuberculosis who were applied directly observation therapy and non-directly observation therapy. Tüberküloz Ve Toraks. 2010;58:44-52.
38. Güler M, Ünsal E, Dursun B, et al. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis: sputum smear and culture conversion in tuberculosis. Int J Clin Pract. 2006;61:231-5.
39. Oursler KK, Moore RD, Bishai WR, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis. 2002;34:752-9.
40. Patel J, De Souza C, Jigjini S. Diabetes and tuberculosis. Ind J Tub. 1977;24:155-8.
41. Lecube A, Pachón G, Petriz J, et al. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS One. 2011;6:e23366.
42. Saxagliptin and tuberculosis. Prescrire Int. 2013;22:17.
43. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. Accessed on 26 Feb 2014. http://onlinelibrary.wiley.com/doi/10.1002/14651858. CD006739.pub2/abstract.
44. WHO: Treatment of Tuberculosis: Guidelines for National Programmes. 2009. Accessed 1 Mar 2010. http://www.who.int/tb/publications/tb-treatmentguidelines/ en/index.html.
45. Maloney N, Britt RC, Rushing GD, et al. Insulin requirements in the intensive care unit in response to infection. Am Surg. 2008;74:845-8.
46. Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother. 2010;54:1068-74.
47. Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848-54.
48. Gadkowski LB, Stout JE. Pharmacokinetics of Rifampicin. Clin Infect Dis. 2007;44:618-9.
49. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169-83.
50. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-84.
51. Wang Q, Ma A, Bygbjerg IC, et al. Rationale and design of a randomized controlled trial of the effect of retinol and vitamin D supplementation on treatment in active pulmonary tuberculosis patients with diabetes. BMC Infect Dis. 2013;13:104.
52. Kolling M, Winkley K, von Deden M. For someone who's rich, it's not a problem". Insights from Tanzania on diabetes health-seeking and medical pluralism among Dar es Salaam's urban poor. Glob Health. 2010;6:8.
53. Griesdale DEG, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Can Med Assoc J. 2009;180:821-7.
54. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.
55. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-61.
56. Van den Berghe G, Mesotten D, Vanhorebeek I. Intensive insulin therapy in the intensive care unit. Can Med Assoc J. 2009;180:799-800.
57. Adepoyibi T, Weigl B, Greb H, et al. New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients [Review article]. Public Health Action. 2013;3:10-7.
58. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomized trial. Lancet. 2011;378:156-67.
59. Prato SD. Mega-trials in type 2 diabetes. From excitement to frustration? Diabetologia. 2009;52:1219-26.
60. Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues. 2006;17:50-5.
61. IDF. IDF diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2013.